RBB

Aidan Heijmans

Amsterdam

      Aidan is a Senior Associate based in RBB’s office in Amsterdam, where he has worked since October 2019.

      He has since advised clients on a range of competition matters before the European Commission, various national competition authorities, most notably those in the Netherlands and the UK, as well as the EU General Court.

      Prior to joining RBB, Aidan obtained an MSc in Industrial Economics and Markets from Universidad Carlos III de Madrid, an MSc in Finance & Investments from Rotterdam School of Management, and a BSc in Economics and Business Economics from Erasmus School of Economics.

      Since joining RBB in 2019, Aidan has advised on a variety of high-profile competition cases before the European Commission, national competition authorities, including those in the Netherlands and the UK, as well as the EU General Court.

      In his role as a consultant competition economist, Aidan has advised clients on mergers, raising both horizontal and vertical concerns, cartel investigations and market inquiries.

      He has advised numerous high-profile clients such as ASDA, Covestro, Illumina, Scania and T-Mobile.

      Aidan’s sectoral experience spans a wide range of sectors, such as automotive, chemicals, pharmaceuticals and life sciences, rolling stock, retail markets and telecommunications.

      A Dutch national, Aidan is a native Dutch speaker and fluent in English.

      Selected Cases

      • Illumina/GRAIL

        Merger, EU

      • ASDA/Co-op stores

        Merger, UK

      • FastNed

        Market inquiry, The Netherlands

      • EG/ASDA

        Merger, UK

      • T-Mobile Nederland/Simpel

        Merger, The Netherlands

      • Covestro/DSM

        Merger, EU & Multi-jurisdictional

      • Trucks cartel

        Damages litigation, EU

      • Alstom/Bombardier

        Merger, EU & Multi-jurisdictional

      A global network of experienced experts

      Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.